Karyopharm stock falls after announcing $100 million financing deal

Investing.com -- Karyopharm Therapeutics (NASDAQ:KPTI) stock fell 13% after the commercial-stage pharmaceutical company announced strategic financing transactions that will provide $100 million in financial flexibility and additional capital.

The Newton, Massachusetts-based company said the financing deal will extend its cash runway into the second quarter of 2026. The transactions, expected to close around October 10, include $67.5 million in financial flexibility and new capital, consisting of $27.5 million in new term loan borrowings and convertible notes, $25 million in deferred interest and royalty payments, and a $15 million temporary reduction in minimum liquidity requirements.

Additionally, holders of approximately $24.25 million of the company’s senior unsecured convertible notes due October 15, 2025, have agreed to exchange their notes for newly issued shares of common stock or pre-funded warrants, plus warrants to purchase common stock.

Karyopharm also entered into a securities purchase agreement for a private placement expected to generate approximately $8.75 million in gross proceeds before expenses.

The company also provided preliminary third-quarter 2025 financial results, projecting total revenue between $42 to $44 million and U.S. XPOVIO net product revenue of approximately $32 million. As of September 30, Karyopharm had approximately $46 million in cash, cash equivalents, restricted cash, and investments before the financing transactions.

"Following the recent completion of enrollment of our Phase 3 SENTRY trial in myelofibrosis, we are excited to announce this strategic financing which is expected to provide us with the resources needed to deliver top-line data from this pivotal trial," said Richard Paulson, President and Chief Executive Officer of Karyopharm.

The company expects to report top-line data from its Phase 3 SENTRY trial in myelofibrosis in March 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.